IPCALAB2023-10-012023-12-31 IPCALAB2023-10-012023-12-31 IPCALAB2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member IPCALAB2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member IPCALAB2023-12-31 IPCALAB2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member IPCALAB2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member IPCALAB2023-10-012023-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member IPCALAB2023-10-012023-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524494 IPCALAB NA IPCA Laboratories Limited Equity 2023-04-01 2024-03-31 2024-02-14 2024-01-22 INR Crores Third quarter 11:30:00 13:30:00 2024-02-14 2024-02-14 Not applicable Single segment Pharmaceuticals 2023-10-01 2023-12-31 Unaudited Standalone 15068300000.00 168900000.00 15237200000.00 4112500000.00 752500000.00 -11100000.00 3343300000.00 272100000.00 630200000.00 4136200000.00 13235700000.00 2001500000.00 0.00 2001500000.00 621000000.00 11100000.00 632100000.00 0.00 1369400000.00 0.00 0.00 0.00 0.00 1369400000.00 -6500000.00 1362900000.00 0.00 0.00 253700000.00 1 5.40 5.40 0.00 0.00 5.40 5.40 1 The above unaudited standalone financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors at their meeting held on February 14, 2024. 2 The Statutory auditors of the Company have carried out Limited Review of the unaudited standalone financial results and have issued their unmodified report thereon. 3 On August 2, 2023, the Company acquired 2,35,01,440 fully paid-up equity shares of Rs. 2/- each of Unichem Laboratories Ltd. representing 33.38% of its paid-up equity share capital @ Rs. 402.25 per share aggregating to Rs. 945.35 crores.The Company has also accepted 1,35,79,571 equity shares of Rs. 2/- each validly tendered in open offer by the public shareholders of Unichem Laboratories Ltd. @ Rs. 440 per equity share aggregating to Rs. 597.50 crores and representing 19.29% of the paid-up equity share capital of the said Unichem Laboratories Ltd.The Company now holds 3,70,81,011 fully paid-up equity shares of Rs. 2/- each of Unichem Laboratories Ltd., representing 52.67% of paid-up share capital of the said company.In view of this, Unichem Laboratories Ltd. has become subsidiary of the Company.Since Subsidiary's Subsidiary is also a subsidiary, 6 wholly owned Subsidiaries of Unichem Laboratories Ltd. have also become Subsidiaries of the Company.The other expenses for quarter ended September 30, 2023 and for nine months period ended December 31, 2023 includes an amount of Rs. 39.04 crores being cost incurred in the acquisition of substantial equity shares of Unichem Laboratories Ltd. 4 The Hon'ble National Company Law Tribunal ('NCLT'), Mumbai Bench, at its hearing held on April 27,2023, has sanctioned the Scheme of Merger of Ramdev Chemical Pvt. Limited (Ramdev) and Tonira Exports Limited (Tonira) , Company's wholly owned subsidiary companies (“Transferor Companies”), with the Company under Sections 230 to 232 of the Companies Act, 2013. Therefore the financial statements of Ramdev and Tonira have been merged with the Company w.e.f. the Appointed Date of April 1, 2022. The comparative quarters presented in these financial results have also been restated for merger effect. 5 The Company has only one operating segment viz. 'Pharmaceuticals'. 6 Figures for the previous period have been regrouped to conform to the figures of the current period. Single segment 2023-04-01 2023-12-31 Unaudited Standalone 46558400000.00 961900000.00 47520300000.00 13249900000.00 2670700000.00 -973900000.00 10029700000.00 966100000.00 1847200000.00 12782000000.00 40571700000.00 6948600000.00 0.00 6948600000.00 2261000000.00 31100000.00 2292100000.00 0.00 4656500000.00 0.00 0.00 0.00 0.00 4656500000.00 -14300000.00 4642200000.00 0.00 0.00 253700000.00 1 18.35 18.35 0.00 0.00 18.35 18.35 Other Expenses 4136200000.00 Other Expenses 12782000000.00 Actuarial loss -6600000.00 Actuarial loss -19600000.00 -6600000.00 -19600000.00 -2100000.00 -6400000.00 Exchange difference in translating the financial statement of foreign operation -3000000.00 Exchange difference in translating the financial statement of foreign operation -1600000.00 -3000000.00 -1600000.00 -1000000.00 -500000.00